Operaciones de insiders

EDGAR

Enveric Biosciences, Inc.

Operaciones informadas por directores, ejecutivos y titulares de más del 10 % en los Formularios 3, 4 y 5 de la SEC, leídas del XML de cada presentación. Los códigos y su redacción son los de la SEC.

El Formulario 4 debe presentarse dentro de los dos días hábiles posteriores a la operación, por lo que las más recientes pueden no estar presentadas aún.

Ventana: operaciones con fecha desde el 16 nov 2025.

Compras en el mercado abierto (código P)
0 operaciones, — acciones
Ventas en el mercado abierto (código S)
0 operaciones, — acciones

Los totales suman las operaciones presentadas que se listan; cuentan lo informado y no miden una dirección.

Mostrando 1–15 de 15

Operaciones de insiders, las más recientes primero, según los Formularios 3, 4 y 5 de la SEC
FechaTitular informanteCódigoAdquirido o enajenadoAccionesPrecio por acción, según lo presentadoValor (derivado)Acciones poseídas despuésDirecta o indirectaCasilla de la Regla 10b5-1NotasFuente
1 jun 2026 Presentado el 3 jun 2026Tucker Joseph Edward Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)201.1240—271.479Directa (D) No
F1
  • F1 Represents the restricted stock units (the RSUs) granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the Company) 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
Abrir presentación 0001883914-26-000003 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 3 jun 2026Schabacker Marcus Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)18.5180—26.418Directa (D) No
F1
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
Abrir presentación 0001645282-26-000002 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 3 jun 2026Facchini Peter J. Officer: Chief Innovation Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)25.0000—27.755Directa (D) No
F1, F2
  • F1 Represents the restricted stock units (the RSUs) granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the Company) 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
  • F2 On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the Reverse Stock Split). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.
Abrir presentación 0001883966-26-000003 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 3 jun 2026PASQUALONE FRANK Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)18.5180—26.423Directa (D) No
F1
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
Abrir presentación 0001597334-26-000002 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 3 jun 2026WEBB MICHAEL D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)18.5180—26.416Directa (D) No
F1
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
Abrir presentación 0001239463-26-000002 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 3 jun 2026Kegler George A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)18.5180—26.418Directa (D) No
F1
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
Abrir presentación 0001761753-26-000003 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 3 jun 2026Coveney Kevin Michael Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)133.3330—180.746Directa (D) No
F1
  • F1 Represents the restricted stock units (the RSUs) granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the Company) 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
Abrir presentación 0001967056-26-000003 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 3 jun 2026DeWitt Sheila Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)18.5180—26.306Directa (D) No
F1
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
Abrir presentación 0002025032-26-000002 Leído del XML de la presentación Disputar esta fila
23 dic 2025 Presentado el 30 dic 2025Kegler George A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)76330—7900Directa (D) No
F1, F2
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
  • F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.
Abrir presentación 0001193125-25-337182 Leído del XML de la presentación Disputar esta fila
23 dic 2025 Presentado el 30 dic 2025DeWitt Sheila Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)76330—7788Directa (D) No
F1, F2
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
  • F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.
Abrir presentación 0001193125-25-337184 Leído del XML de la presentación Disputar esta fila
23 dic 2025 Presentado el 30 dic 2025Coveney Kevin Michael Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)40.1980—47.413Directa (D) No
F1, F2
  • F1 Represents the restricted stock units (the RSUs) granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the Company) 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
  • F2 On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the Reverse Stock Split). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.
Abrir presentación 0001193125-25-337171 Leído del XML de la presentación Disputar esta fila
23 dic 2025 Presentado el 30 dic 2025WEBB MICHAEL D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)76330—7898Directa (D) No
F1, F2
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
  • F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.
Abrir presentación 0001193125-25-337172 Leído del XML de la presentación Disputar esta fila
23 dic 2025 Presentado el 30 dic 2025PASQUALONE FRANK Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)76330—7904Directa (D) No
F1, F2
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
  • F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.
Abrir presentación 0001193125-25-337179 Leído del XML de la presentación Disputar esta fila
23 dic 2025 Presentado el 30 dic 2025Tucker Joseph Edward Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)60.2960—70.355Directa (D) No
F1, F2
  • F1 Represents the restricted stock units (the RSUs) granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the Company) 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
  • F2 On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the Reverse Stock Split). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.
Abrir presentación 0001193125-25-337175 Leído del XML de la presentación Disputar esta fila
23 dic 2025 Presentado el 30 dic 2025Schabacker Marcus Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)76330—7900Directa (D) No
F1, F2
  • F1 Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the Plan). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
  • F2 On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the January Reverse Stock Split). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (theOctober Reverse Stock Split together with the January Reverse Stock Split, the Reverse Stock Splits). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.
Abrir presentación 0001193125-25-337178 Leído del XML de la presentación Disputar esta fila

Titulares institucionales (Formulario 13F)

Trimestre terminado el 2026-09-30: 7211 presentaciones leídas, la última del 13 nov 2026. Trimestre anterior terminado el 2026-06-30: 9150 presentaciones leídas.

Mostrando 1–18 de 18

Titulares institucionales, la posición mayor primero, según lo presentado
GestorAcciones o principalValor según lo presentadoDiferencia con el trimestre anteriorFuente
AdvisorShares Investments LLC 43.783 SH64.361 dólaresMayor en 8366 Trimestre anterior: 35.417Abrir presentación 0001829126-26-012138 Presentado el 9 nov 2026 Disputar esta fila
VANGUARD FIDUCIARY TRUST CO 33.784 SH49.662 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000933478-26-000017 Presentado el 13 nov 2026 Disputar esta fila
StoneX Group Inc. Informado en parte bajo otro gestor27.986 SH41.051 dólaresMayor en 16.172 Trimestre anterior: 11.814Abrir presentación 0000913760-26-000042 Presentado el 3 nov 2026 Disputar esta fila
JANE STREET GROUP, LLC Informado en parte bajo otro gestor19.444 SH28.874 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001595888-26-000162 Presentado el 12 nov 2026 Disputar esta fila
GEODE CAPITAL MANAGEMENT, LLC Informado en parte bajo otro gestor17.794 SH26.156 dólaresMayor en 6000 Trimestre anterior: 11.794Abrir presentación 0001214717-26-000012 Presentado el 6 nov 2026 Disputar esta fila
VANGUARD CAPITAL MANAGEMENT LLC 14.912 SH21.921 dólaresSin cambios Trimestre anterior: 14.912Abrir presentación 0002100119-26-001711 Presentado el 13 nov 2026 Disputar esta fila
SBI Securities Co., Ltd. 3089 SH4587 dólaresMayor en 413 Trimestre anterior: 2676Abrir presentación 0001851815-26-000004 Presentado el 22 oct 2026 Disputar esta fila
Farther Finance Advisors, LLC 3000 SH4455 dólaresSin cambios Trimestre anterior: 3000Abrir presentación 0001992825-26-000006 Presentado el 8 oct 2026 Disputar esta fila
JONES FINANCIAL COMPANIES LLLP Informado en parte bajo otro gestor1000 SH1500 dólaresSin cambios Trimestre anterior: 1000Abrir presentación 0001193125-26-459442 Presentado el 13 nov 2026 Disputar esta fila
UBS Group AG Informado en parte bajo otro gestor434 SH643 dólaresMayor en 233 Trimestre anterior: 201Abrir presentación 0001610520-26-000121 Presentado el 10 nov 2026 Disputar esta fila
BlackRock, Inc. Informado en parte bajo otro gestor51 SH76 dólaresSin cambios Trimestre anterior: 51Abrir presentación 0002012383-26-003985 Presentado el 13 nov 2026 Disputar esta fila
Root Financial Partners, LLC Informado en parte bajo otro gestor13 SH19 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001977181-26-000005 Presentado el 21 oct 2026 Disputar esta fila
Arax Advisory Partners Informado en parte bajo otro gestor8 SH12 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001586767-26-000009 Presentado el 12 nov 2026 Disputar esta fila
FMR LLC Informado en parte bajo otro gestor2 SH3 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000315066-26-002964 Presentado el 10 nov 2026 Disputar esta fila
DANSKE BANK A/S 1 SH1 dólaresSin cambios Trimestre anterior: 1Abrir presentación 0001104659-26-124081 Presentado el 9 nov 2026 Disputar esta fila
MORGAN STANLEY Informado en parte bajo otro gestor1 SH1 dólaresMenor en 10.732 Trimestre anterior: 10.733Abrir presentación 0000895421-26-000309 Presentado el 13 nov 2026 Disputar esta fila
CITIGROUP INC Informado en parte bajo otro gestor1 SH1 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000831001-26-000052 Presentado el 4 nov 2026 Disputar esta fila
OSAIC HOLDINGS, INC. Informado en parte bajo otro gestor1 SH1 dólaresSin cambios Trimestre anterior: 1Abrir presentación 0001677044-26-000011 Presentado el 12 nov 2026 Disputar esta fila
Gestores del trimestre anterior sin presentación leída para el último

Quizá simplemente no hayan presentado aún: estar ausente de las presentaciones leídas del último trimestre no equivale a una posición vendida.

  • Sio Capital Management, LLC 180.000 SH
  • Ikarian Capital, LLC 100.002 SH
  • RENAISSANCE TECHNOLOGIES LLC 32.058 SH
  • ARMISTICE CAPITAL, LLC 32.000 SH
  • BOOTHBAY FUND MANAGEMENT, LLC 30.142 SH
  • XTX Topco Ltd 18.990 SH
  • HRT FINANCIAL LP 15.458 SH
  • CITADEL ADVISORS LLC 13.965 SH
  • Virtu Financial LLC 10.690 SH
  • Tower Research Capital LLC (TRC) 4984 SH
  • Integrated Wealth Concepts LLC 702 SH
  • NATIONAL BANK OF CANADA /FI/ 1 SH
  • WELLS FARGO COMPANY/MN 1 SH
  • El Formulario 13F cubre solo posiciones largas en valores de la Sección 13(f): ni posiciones cortas ni valores fuera de esa lista.
  • Un gestor que aún no ha presentado el último trimestre está ausente, no en cero; las presentaciones vencen hasta 45 días después del cierre del trimestre.
  • Una diferencia es la que hay entre dos instantáneas de cierre de trimestre, no una operación.
  • Una posición informada bajo otro gestor puede aparecer también en la presentación de ese gestor; las filas no se suman.
  • No se muestran las posiciones que la lista de valores no puede atribuir a esta empresa o atribuye de forma ambigua.

Titulares del 5 % (Anexos 13D y 13G)

Aquí se leen los anexos presentados en el formato estructurado de la SEC (desde finales de 2024). Los anteriores son texto libre y no se leen.

Titulares del 5 %, el evento más reciente primero, según lo presentado
TitularPorcentaje de la claseAcciones en poderFecha del eventoFormularioFuente
Sio Capital Management, LLC Common Stock, par value, $0.01 per share7.37330.000,0009/30/2026 Presentado el 3 nov 2026SCHEDULE 13GAbrir presentación 0001214659-26-013680 Disputar esta fila
Armistice Capital, LLC Common stock, par value $0.01 per share9.99405.092,0006/30/2026 Presentado el 14 ago 2026SCHEDULE 13GAbrir presentación 0001172661-26-003572 Disputar esta fila
Steven Boyd Common stock, par value $0.01 per share9.99405.092,0006/30/2026 Presentado el 14 ago 2026SCHEDULE 13GAbrir presentación 0001172661-26-003572 Disputar esta fila
Lind Global Fund III LP Common Stock, $0.01 par value1.349.36606/30/2026 Presentado el 14 ago 2026SCHEDULE 13G/AEnmienda 2Abrir presentación 0000929638-26-003073 Disputar esta fila
Lind Global Partners III LLC Common Stock, $0.01 par value1.349.36606/30/2026 Presentado el 14 ago 2026SCHEDULE 13G/AEnmienda 2Abrir presentación 0000929638-26-003073 Disputar esta fila
EASTON JEFF Common Stock, $0.01 par value1.451.86606/30/2026 Presentado el 14 ago 2026SCHEDULE 13G/AEnmienda 2Abrir presentación 0000929638-26-003073 Disputar esta fila
Ayrton Capital LLC Common Stock, $0.01 par value per share2.93111.145,0006/30/2026 Presentado el 13 ago 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0001493152-26-037652 Disputar esta fila
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B Common Stock, $0.01 par value per share2.93111.145,0006/30/2026 Presentado el 13 ago 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0001493152-26-037652 Disputar esta fila
Waqas Khatri Common Stock, $0.01 par value per share2.93111.145,0006/30/2026 Presentado el 13 ago 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0001493152-26-037652 Disputar esta fila
Lind Global Fund III LP Common Stock, $0.01 par value7.76158.73203/31/2026 Presentado el 15 may 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0000929638-26-001905 Disputar esta fila
Lind Global Partners III LLC Common Stock, $0.01 par value7.76158.73203/31/2026 Presentado el 15 may 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0000929638-26-001905 Disputar esta fila
EASTON JEFF Common Stock, $0.01 par value7.87161.23203/31/2026 Presentado el 15 may 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0000929638-26-001905 Disputar esta fila
Lind Global Fund III LP Common Stock, $0.01 par value9.99141.26501/28/2026 Presentado el 4 feb 2026SCHEDULE 13GAbrir presentación 0000929638-26-000500 Disputar esta fila
Lind Global Partners III LLC Common Stock, $0.01 par value9.99141.26501/28/2026 Presentado el 4 feb 2026SCHEDULE 13GAbrir presentación 0000929638-26-000500 Disputar esta fila
EASTON JEFF Common Stock, $0.01 par value9.99141.26501/28/2026 Presentado el 4 feb 2026SCHEDULE 13GAbrir presentación 0000929638-26-000500 Disputar esta fila
Mitchell P. Kopin Common Stock, par value $0.01 per share4.9971.246,0001/27/2026 Presentado el 2 feb 2026SCHEDULE 13GAbrir presentación 0001213900-26-010971 Disputar esta fila
Daniel B. Asher Common Stock, par value $0.01 per share4.9971.246,0001/27/2026 Presentado el 2 feb 2026SCHEDULE 13GAbrir presentación 0001213900-26-010971 Disputar esta fila
Intracoastal Capital LLC Common Stock, par value $0.01 per share4.9971.246,0001/27/2026 Presentado el 2 feb 2026SCHEDULE 13GAbrir presentación 0001213900-26-010971 Disputar esta fila
AdvisorShares Trust Common Stock, $0.01 par value1.6616.97412/31/2025 Presentado el 5 ene 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0000929638-26-000009 Disputar esta fila
Mitchell P. Kopin Common Stock, par value $0.01 per share4.9931.353,0012/11/2025 Presentado el 17 dic 2025SCHEDULE 13GAbrir presentación 0001213900-25-123020 Disputar esta fila
Daniel B. Asher Common Stock, par value $0.01 per share4.9931.353,0012/11/2025 Presentado el 17 dic 2025SCHEDULE 13GAbrir presentación 0001213900-25-123020 Disputar esta fila
INTRACOASTAL CAPITAL, LLC Common Stock, par value $0.01 per share4.9931.353,0012/11/2025 Presentado el 17 dic 2025SCHEDULE 13GAbrir presentación 0001213900-25-123020 Disputar esta fila
Northstrive Fund II LP Common Stock, $0.01 par value per share00,0012/09/2025 Presentado el 10 dic 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0001213900-25-120055 Disputar esta fila
Braeden Lichti Common Stock, $0.01 par value per share00,0012/09/2025 Presentado el 10 dic 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0001213900-25-120055 Disputar esta fila
Braeden Lichti Common Stock, $0.01 par value per share00,0012/09/2025 Presentado el 10 dic 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0001213900-25-120056 Disputar esta fila
Northstrive Fund II LP Common Stock, $0.01 par value per share00,0012/09/2025 Presentado el 10 dic 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0001213900-25-120056 Disputar esta fila
Braeden Lichti Common Stock, $0.01 par value per share5.0129.920,0012/03/2025 Presentado el 5 dic 2025SCHEDULE 13GAbrir presentación 0001213900-25-118884 Disputar esta fila
Northstrive Fund II LP Common Stock, $0.01 par value per share4.3425.915,0012/03/2025 Presentado el 5 dic 2025SCHEDULE 13GAbrir presentación 0001213900-25-118884 Disputar esta fila
Northstrive Fund II LP Common Stock, $0.01 par value per share4.3425.915,0012/03/2025 Presentado el 5 dic 2025SCHEDULE 13GAbrir presentación 0001213900-25-118848 Disputar esta fila
Braeden Lichti Common Stock, $0.01 par value per share5.0129.920,0012/03/2025 Presentado el 5 dic 2025SCHEDULE 13GAbrir presentación 0001213900-25-118848 Disputar esta fila
Ayrton Capital LLC Common Stock, $0.01 par value per share9.99658.465,0009/30/2025 Presentado el 13 nov 2025SCHEDULE 13GAbrir presentación 0001493152-25-022260 Disputar esta fila
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B Common Stock, $0.01 par value per share9.99658.465,0009/30/2025 Presentado el 13 nov 2025SCHEDULE 13GAbrir presentación 0001493152-25-022260 Disputar esta fila
Waqas Khatri Common Stock, $0.01 par value per share9.99658.465,0009/30/2025 Presentado el 13 nov 2025SCHEDULE 13GAbrir presentación 0001493152-25-022260 Disputar esta fila
AdvisorShares Trust Common Stock, $0.01 par value6.27203.67909/30/2025 Presentado el 3 oct 2025SCHEDULE 13GAbrir presentación 0000929638-25-003807 Disputar esta fila
Mitchell P. Kopin Common Stock, par value $0.01 per share0.419.333,0009/18/2025 Presentado el 24 sept 2025SCHEDULE 13GAbrir presentación 0001213900-25-091199 Disputar esta fila
Daniel B. Asher Common Stock, par value $0.01 per share0.419.333,0009/18/2025 Presentado el 24 sept 2025SCHEDULE 13GAbrir presentación 0001213900-25-091199 Disputar esta fila
Intracoastal Capital LLC Common Stock, par value $0.01 per share0.419.333,0009/18/2025 Presentado el 24 sept 2025SCHEDULE 13GAbrir presentación 0001213900-25-091199 Disputar esta fila

El porcentaje es de la clase que indica la presentación, según lo declaró el titular. Los miembros de un grupo informan cada uno las acciones del grupo, por lo que las filas no se suman.

Qué se leyó

2.093.437 presentaciones leídas, del 14 jun 2004 al 13 nov 2026: Formularios 3, 3/A, 4, 4/A, 5, 5/A.

Algunos años pueden estar incompletos mientras se sigue leyendo el archivo. Un año con pocas presentaciones aquí no afirma que se hicieran pocas.

Presentaciones leídas, por año de presentación
Año de presentaciónPresentaciones leídas
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202240.015
2023199.811
2024186.415
2025235.520
2026254.737

Las presentaciones anteriores a que la SEC exigiera XML se listan, pero no se extraen.

Volver a Enveric Biosciences, Inc.